An international group of researchers have discovered that analyzing blood tests for changes in the DNA code can identify individuals at high risk of developing acute myeloid leukaemia (AML) years before diagnosis.
Choosing when to stop immunotherapy is an extremely difficult decision process – in this blog piece melanoma survivor T.J. Sharpe shares his thoughts on the recent KEYNOTE-006 data.
Best of ASCO18: key takeaways & the practice-changing talks
Presentations from this year’s American Society of Clinical Oncology Annual Meeting (ASCO, 1–5 June 2018, IL, USA) unearthed a wealth of exciting data across the oncology spectrum. We have brought together our top takeaways from the 5 days of ASCO 2018.
ASCO18: Day 1 update
Today marked the first day of ASCO 2018, here in Chicago. The conference has already been packed with new advancements and data from studies that could significantly impact clinical practice within oncology. Take a look at some of our highlights.